熱門資訊> 正文
89 bio提供2025年业务更新和展望
2025-01-13 21:36
- 89bio (NASDAQ:ETNB), a clinical-stage biopharmaceutical company, on Monday provided a corporate update and business outlook for 2025.
- The company completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG) and said the topline 26-week data is expected in the second half of 2025.
- The Phase 3 ENLIGHTEN program in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continues to enroll patients across both trials.
- Cash, cash equivalents, and marketable securities totaled approximately $440 million as of December 31, 2024.
- “We continue to advance our Phase 3 programs toward potential Biologics License Application (BLA) and Marketing Authorization Application (MAA) filings, aiming to transform care for patients living with MASH and SHTG,” said Rohan Palekar, CEO of 89bio.
- 89bio (NASDAQ:ETNB) shares were up 2.46% in pre-market trading on Monday.
More on 89bio
- 89bio: Surviving A Competitive Space - For Now
- 89bio drops 2%, prices $125M stock offering
- 89bio announces proposed underwritten public offering of common stock and pre-funded warrants
- Seeking Alpha’s Quant Rating on 89bio
- Historical earnings data for 89bio
推薦文章
一周IPO丨中慧生物暗盤飆漲162%，中籤一手賺超4000港元；「減肥藥概念」銀諾醫藥招股中
機器人投資風口來襲！世界級盛會催化下，哪些機會不容錯過？
華盛早報丨美國退休金突發！401K可投資加密貨幣；火箭製造商FLY上市首日暴漲34%
美國養老金投資或迎鉅變，特朗普頒令為401(k)納入加密貨幣等資產鋪路
外盤頭條：OpenAI發佈最強GPT-5；特朗普頒令允許養老金投資另類資產
美股機會日報丨重大利好！特朗普將允許養老金投資加密貨幣；多鄰國績后狂飆26%
一圖看懂 | 中芯國際Q2營收22.09億美元，同比增長16.2%，股東應占利潤同比減少19.5%
新股申購 | 「減肥藥概念」 銀諾醫藥-B一手入場費3773.68港元，引入邁富時等基石投資者
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
